{
    "clinical_study": {
        "@rank": "136337", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1", 
                "arm_group_type": "Experimental", 
                "description": "Dosing regimen 1"
            }, 
            {
                "arm_group_label": "Cohort 2", 
                "arm_group_type": "Experimental", 
                "description": "Dosing regimen 2"
            }, 
            {
                "arm_group_label": "Cohort 3", 
                "arm_group_type": "Experimental", 
                "description": "Dosing regimen 3"
            }, 
            {
                "arm_group_label": "Cohort 4", 
                "arm_group_type": "Experimental", 
                "description": "Dosing regimen 4"
            }, 
            {
                "arm_group_label": "Cohort 5", 
                "arm_group_type": "Experimental", 
                "description": "Dosing regimen 5"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a phase 1, randomized, double-blind, placebo-controlled study evaluating the safety,\n      tolerability, pharmacokinetic (PK) profile, and immunogenicity of REGN2222 ascending in\n      cohorts of healthy adult volunteers."
        }, 
        "brief_title": "Study of the Safety and Tolerability of REGN2222(SAR438584) in Healthy Adult Volunteers", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy Volunteers", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. A healthy man or woman aged 18 to 60 years\n\n          2. Body mass index between 18.0 kg/m2 and 32.0 kg/m2, inclusive\n\n          3. Willing and able to comply with clinic visits and study-related procedures\n\n          4. Provide signed informed consent\n\n        Exclusion Criteria:\n\n          1. Serum hemoglobin, creatinine, alkaline phosphatase, CPK, and/or hepatic enzymes\n             (aspartate aminotransferase [AST] and alanine aminotransferase [ALT], total bilirubin\n             [unless the investigator has evidence that increased bilirubin corresponds to a\n             Gilbert's type syndrome with elevated indirect bilirubin]) that is >1.5 the upper\n             limit of normal (ULN), or any laboratory findings showing evidence of organ\n             dysfunction or any clinically significant abnormalities from the normal range, as\n             determined by the investigator at the screening visit\n\n          2. Use of any concomitant medications within 30 days or at least 5 half-lives, whichever\n             is longer, of the screening visit, including prescription medications (except\n             contraceptives), nutritional supplements, and over-the-counter medications (except\n             acetaminophen)\n\n          3. Hospitalization for any reason within 60 days of the screening visit\n\n          4. History of or positive human immunodeficiency virus (HIV) screen result at the\n             screening visit\n\n          5. History of or positive blood test result for hepatitis B surface antigen and/or\n             hepatitis C virus antibody at the screening visit\n\n          6. History of autoimmune disease\n\n          7. History of respiratory disease (e.g, asthma, chronic obstructive pulmonary disease)\n\n          8. History of drug or alcohol abuse within 1 year prior to the screening visit\n\n          9. Participation in any clinical research study evaluating another investigational drug\n             or therapy within 30 days, or within at least 5 half-lives, of the investigational\n             drug (whichever is longer) prior to the screening visit\n\n         10. Pregnant or breastfeeding woman\n\n         11. Sexually active men* or women of childbearing potential** who are unwilling to\n             practice adequate contraception during the study, and up to 3 months after the last\n             dose of the study drug (adequate contraceptive measures include stable use of oral\n             contraceptives or other prescription pharmaceutical contraceptives for 2 or more\n             menstrual cycles prior to screening; intrauterine device; bilateral tubal ligation;\n             vasectomy; condom plus contraceptive sponge, foam, or jelly, or diaphragm plus\n             contraceptive sponge, foam, or jelly)\n\n               -  Contraception is not required for men with documented vasectomy.\n                  **Postmenopausal women must be amenorrheic for at least 12 months in order not\n                  to be considered of childbearing potential.  Contraception is not required for\n                  women with documented hysterectomy or tubal ligation."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "132", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 21, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02121080", 
            "org_study_id": "R2222-HV-1326"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Cohort 1", 
                    "Cohort 2", 
                    "Cohort 3", 
                    "Cohort 4", 
                    "Cohort 5"
                ], 
                "intervention_name": "REGN2222(SAR438584)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Cohort 1", 
                    "Cohort 2", 
                    "Cohort 3", 
                    "Cohort 4", 
                    "Cohort 5"
                ], 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 13, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Daytona Beach", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Evansville", 
                        "country": "United States", 
                        "state": "Indiana"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "5", 
        "overall_contact": {
            "email": "clinicaltrials@regeneron.com", 
            "last_name": "Clinical Trials Administrator"
        }, 
        "overall_official": {
            "affiliation": "Regeneron Pharmaceuticals", 
            "last_name": "Clinical Trial Management", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary endpoint in the study is the incidence and severity of treatment-emergent adverse events (TEAEs) from day 1 through the end of study (EOS/ up to 20 weeks) in participants treated with REGN2222 or placebo.", 
            "measure": "Safety", 
            "safety_issue": "Yes", 
            "time_frame": "from day 1 up to week 20 (EOS)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02121080"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Serum concentration of REGN2222 over time up to week 20", 
                "measure": "Serum concentration", 
                "safety_issue": "No", 
                "time_frame": "from day 1 over time up to week 20"
            }, 
            {
                "description": "The presence or absence of antibodies against REGN2222 over time up to week 20", 
                "measure": "Presence or absence of antibodies", 
                "safety_issue": "No", 
                "time_frame": "from day 1 over time up to week 20"
            }
        ], 
        "source": "Regeneron Pharmaceuticals", 
        "sponsors": {
            "collaborator": {
                "agency": "Sanofi", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Regeneron Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}